Clinical Trial Update: Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating pomalidomide, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Pomalidomide (Pomalidomide)

Snippet

Sponsor: Mayo Clinic | Conditions: Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-04-17